Drug review: Ibrutinib
Ibrutinib is an irreversible BTK inhibitor, characterized by high selectivity and potency. It has revolutionized the therapy of B-cell lymphomas, especially chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Importantly, it has expanded the armamentarium for those patients who are refracto...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2020-01-01
|
| coleção: | Indian Journal of Medical and Paediatric Oncology |
| Assuntos: | |
| Acesso em linha: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=3;spage=383;epage=392;aulast= |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|